8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 8, 2009
GENTA INCORPORATED
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| |
|
|
| 0-19635 |
|
33-0326866 |
| (Commission File Number)
|
|
(IRS Employer Identification No.) |
| |
|
|
| 200 Connell Drive |
|
|
| Berkeley Heights, NJ |
|
07922 |
| (Address of Principal Executive Offices)
|
|
(Zip Code) |
(908) 286-9800
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the Registrant under any of the following provisions:
| |
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12) |
| |
|
|
| o |
|
Pre -commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
|
| o |
|
Pre -commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On January 8, 2009, Genta Incorporated, (the Company), announced that two new patents related to
the Company’s franchise in gallium-containing products have issued in the United States.
Applications similar to these patents are pending worldwide, and several additional applications
that address other compositions and uses have been filed in the U.S. and other territories. These
patents and filings provide for claims of compositions and uses of gallium compounds that can be
taken by mouth over extended periods for treatment of skeletal diseases as well as other
indications.
The two new patents, US 7,354,952B2 and US 7,456,215B2, provide for the therapeutic use of gallium
complexed with various agents that increase the oral bioavailability of the active ingredient and
yield superior pharmacokinetics compared with the active ingredient used alone.
|
|
|
| Item 9.01 |
|
Financial Statements and Exhibits. |
| |
|
|
|
|
| Exhibit |
|
|
| Number |
|
Description |
| |
99.1 |
|
|
Press Release of the Company dated January 8, 2009 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
| |
GENTA INCORPORATED
|
|
| Date: January 8, 2009 |
By: |
/s/ GARY SIEGEL
|
|
| |
|
Name: |
Gary Siegel |
|
| |
|
Title: |
Vice President, Finance |
|
| |
EXHIBIT INDEX
| |
|
|
|
|
|
|
| Exhibit |
|
|
|
Sequentially |
| Number |
|
Description |
|
Numbered Page |
| |
99.1 |
|
|
Press Release of the Company dated January 8, 2009
|
|
|